Evaluating Diagnosis and Treatment of Oral and Esophageal Candidiasis in Ugandan AIDS Patients

Maurizio Ravera, Alberto Reggiori, Anna Maria Agliata, and Roberto Pidoto Rocco
Regional Teaching Hospital, Hoima, Uganda

A randomized cross-over clinical and endoscopic evaluation of 85 Ugandan patients showed that esophageal candidiasis in AIDS patients with oral candidiasis could be managed without endoscopy and biopsies. Oral lesions, especially when accompanied by esophageal symptoms, were sufficient for diagnosis. Miconazole was more effective than nystatin in treating esophageal candidiasis and could be a valid alternative to more expensive azolic drugs in developing countries.

The Study
From September 1994 to December 1995, 320 consecutive AIDS patients were observed at the Gastroenterology Department of Hoima Hospital in Uganda. Among them, 85 (45 women, 40 men, mean age 27.1, standard deviation [SD] 5.3 years) fulfilled admission criteria: positive HIV test or clinical diagnosis of AIDS and presence of oral patchy white plaques as markers of oral candidiasis. The district medical officer and the hospital medical superintendent granted approval for the study, and informed consent was obtained from each patient. Patients were considered symptomatic if they had any of the following symptoms: odinophagia, dysphagia, or retrosternal burning pain.

All patients were hospitalized, and the upper digestive tract was examined endoscopically. The diagnosis of esophageal candidiasis was made at the examination. All patients had the
same spectrum of lesions: patchy white plaques, confluent pseudomembrane, and friable mucosa. Routine histopathologic assessment was not performed, mainly because of cost.

Patients were randomly assigned to the nystatin or miconazole regimen; a stratified randomization method was used to balance treatment groups by esophageal symptoms, age, and sex (Table). Nystatin tablets were given at a dose of 1,000,000 I.U. every 8 hours for 7 days (according to Uganda Ministry of Health 1993 National Standard Treatment Guidelines), while miconazole tablets were administered at a dose of 250 mg every 6 hours for 7 days (25). At a mean follow-up of 7.6 days (SD 0.9), the patients’ symptoms were reassessed, and the upper digestive tract was reexamined endoscopically. The endoscopist was blind to the treatment used. Patients given nystatin who still had candidiasis were placed on the miconazole regimen and tested for candidiasis 1 week later.

### Findings

Most (90.8%) (42 female, 35 male, mean age 28.0 ± 5.8 years) of the study participants had both oral and esophageal candidiasis. Forty (47.1%) had esophageal symptoms, and all had esophageal candidiasis at endoscopy. Sensitivity, specificity, and the positive and negative predictive values of esophageal symptoms as markers of esophageal infection were 83.3% (confidence interval [CI] 69.2 to 92.0), 100% (CI 88.3 to 100), 100% (CI 89.1 to 100), and 82.2% (CI 67.4 to 91.5), respectively.

Esophageal symptoms disappeared in 10 (27.0%) of the 37 patients in the nystatin group and in 38 (95.0%) of 40 patients in the miconazole group (Yates chi-square = 34.99, p < 0.001). Oral candidiasis was cured in all patients in both groups; esophageal candidiasis was cured in 8 (21.6%) patients in the nystatin group and in 37 (92.5%) patients in the miconazole group (Yates chi-square = 36.89, p < 0.001). Of the 29 patients who did not respond to nystatin, 27 (93.1%) were cured with miconazole (Figure). No adverse effects were observed in either group.

More than 90% of AIDS patients with oral candidiasis in this study also had esophageal candidiasis, thus confirming that such an association is also very strong in Uganda (14,26). A little more than half (51.9%) of 77 patients with esophageal candidiasis also had esophageal symptoms. Our findings and those of other studies support the observation that esophageal candidiasis could be suspected if oral thrush is present, especially when esophageal symptoms are associated (10,14,26,27). Thus, in tropical countries, endoscopic assessment and biopsies might best be reserved for patients who have esophageal symptoms after receiving prolonged antifungal treatment to confirm diagnosis of candidiasis or to determine other infectious causes of this symptoms (e.g., herpes simplex virus infection, cytomegalovirus infection, cryptosporidiosis) (2,23).

Although our study was not designed to detect recurrence of candidiasis, esophageal candidiasis is likely to recur in AIDS patients within 12 months from any antifungal treat-

---

**Table. Characteristics of patients participating in the study**

<table>
<thead>
<tr>
<th>Condition</th>
<th>No.</th>
<th>Mean age (yr) (S.D.)</th>
<th>Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral candidiasis</td>
<td>85</td>
<td>24.0 (6.7)</td>
<td>32 / 53</td>
</tr>
<tr>
<td>Esophageal symptoms</td>
<td>40</td>
<td>23.9 (6.1)</td>
<td>7 / 23</td>
</tr>
<tr>
<td>Nystatin group</td>
<td>20</td>
<td>23.7 (6.6)</td>
<td>8 / 12</td>
</tr>
<tr>
<td>Miconazole group</td>
<td>20</td>
<td>23.7 (6.6)</td>
<td>8 / 12</td>
</tr>
<tr>
<td>Esophageal candidiasis</td>
<td>77</td>
<td>23.7 (6.4)</td>
<td>27 / 50</td>
</tr>
<tr>
<td>Nystatin group</td>
<td>37</td>
<td>24.2 (6.5)</td>
<td>12 / 22</td>
</tr>
<tr>
<td>Miconazole group</td>
<td>40</td>
<td>23.4 (6.1)</td>
<td>15 / 25</td>
</tr>
</tbody>
</table>

*aEsophageal symptoms are any of the following: odinophagia, dysphagia, retrosternal burning pain.*

---

**Figure. Esophageal candidiasis treatment flow.**
ment; if it does, response to therapy is worse than response to initial therapy (28). For this reason, as well as the possibility of resistance to miconazole (sporadic cases have been reported [29]), more expensive azolic drugs (e.g., fluconazole) should be reserved for recurrences of the disease; the disease should be treated initially with less expensive, but more effective drugs (e.g., miconazole).

In sum, AIDS patients with oral candidiasis in countries similar to Uganda can be managed without endoscopic and bioptic assessments since oral lesions are typical and a high prevalence of esophageal involvement is expected (with or without symptoms) (>90% of cases in our study). In our patients, nystatin had a very low cure rate in the treatment of esophageal candidiasis in AIDS patients; however, it could still play a role in the treatment of oral candidiasis, especially in nonimmunocompromised patients, in whom concomitant esophageal involvement is less common. On the other hand, miconazole, a medium-priced azolic drug, was very effective and could be a valid alternative to more expensive azolic drugs in developing countries.

Acknowledgments

We thank Dr. G. Oundo, medical superintendent, and the staff of Hoima Hospital.

This study was funded by International Service Volunteers' Association, Kampala, Uganda.

Dr. Ravera is a specialist in gastroenterology and digestive endoscopy. A researcher at the Italian National Health Institute, he serves as site coordinator/monitor of the UNAIDS PETRA study at Nsambya Hospital, Kampala, Uganda. His research interests include gastroenterology, endoscopy, infectious diseases, and HIV/AIDS.

References


